2026 H1 - tulosraportti
58 päivää sitten
‧45 min
Tarjoustasot
Määrä
Osto
-
Myynti
Määrä
-
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| 3 206 | - | - | ||
| 1 000 | - | - | ||
| 1 542 | - | - | ||
| 7 035 | - | - | ||
| 647 | - | - |
Huomioi, että vaikka osakkeisiin säästäminen on pitkällä aikavälillä tuottanut hyvin, tulevasta tuotosta ei ole takeita. On olemassa riski, että et saa sijoittamiasi varoja takaisin.
Rahastoja ja ETF:iä jotka omistavat osaketta
Mikään rahasto ei ilmoita osaketta kymmenen suurimman omistuksensa joukossa.
Asiakkaat katsoivat myös
Yhtiötapahtumat
Datan lähde: Quartr| Seuraava tapahtuma | |
|---|---|
2026 H2 - tulosraportti 26.2.2027 |
| Menneet tapahtumat | ||
|---|---|---|
2026 H1 - tulosraportti 28.8. | ||
2025 H2 - tulosraportti 26.2. | ||
2025 H1 - tulosraportti 29.8.2025 | ||
2024 H2 - tulosraportti 26.2.2025 | ||
2024 H1 - tulosraportti 30.8.2024 |
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Foorumi
Liity keskusteluun Nordnet Socialissa
·4 t sittenSharing this from Randy Peterson, the Q3/2026 update on manufacturing and supply chain in radiopharma. It hits the isotopes well because it shows how actively capacity is being built right now for the most important ones: Ac-225 (e.g. Actineer and BMS/RayzeBio), Lu-177 (ITM, Curium/MURR), Pb-212 (OranoMed), At-211 (Ionetix) and Cu-64 (C-Ray). At the same time, we see major investments in Canada (AtomVie, Isologic, Jubilant) and elsewhere to secure supply and scalable production. Fine overview, even though Thor Medical is unfortunately omitted. https://www.linkedin.com/pulse/q32026-radiopharmaceutical-newspart-ii-manufacturing-supply-peterson-myqbc?utm_source=share&utm_medium=member_ios&utm_campaign=share_via
1 päivä sitten
ChatGPT: What does this concretely mean for Thor Medical? The study provides positive signals for the further development of a new type of treatment against prostate cancer that has spread to other parts of the body. The results from the first study, TheraPb phase 1, support the researchers moving forward with the treatment ²¹²Pb-ADVC001. Now the treatment is being investigated further in phase 2, where the researchers are testing two doses – 160 and 200 MBq – and looking at how the dosing can be optimized, among other things in combination with other treatments. Here is the most important connection: AdvanCell, the company developing ADVC001, is already a customer of Thor Medical. Thor Medical supplies thorium-228 (Th-228), which AdvanCell uses as starting material to produce lead-212 (Pb-212) for the cancer treatment. In August 2025, AdvanCell increased its agreed purchase commitment from 100 to 150 million NOK over five years – an increase of 50 percent. It is also important that Thor Medical has several customers and programs than AdvanCell alone. The company reported a total order backlog of around 850 million NOK at the end of 2025, distributed across eight radiopharmaceutical companies. This provides several potential drivers for future demand.  My conclusion: This is relevant and potentially important news for Thor Medical. It supports the medical and commercial foundation for one of the company's customer's development programs. But for now, it is primarily a confirmation of the potential – not documentation that Thor Medical's revenues or profits will increase as a result of this exact study. For shareholders, it is crucial going forward whether phase 2 confirms the results, whether AdvanCell increases its actual orders, and whether Thor Medical manages to scale production and deliver with profitability.
·1 päivä sittenDid you know? Thor medical's order backlog of 850 million applies exclusively to Th228, which means that everything concerning Pb212 (and for that matter Ra-224) sales is extra revenue on top. When Scatec and several large investors pull out the shopping cart in a several times oversubscribed private placement, and make extra good room in the trunk to bring along as much as possible. Then one can perhaps think a little about how much revenue lies in the Pb212 initiative. I know at least that I wouldn't bet money on a private placement that makes revenues and margins worse, so here it is probably the opposite. Management has confirmed that these are separate revenue opportunities. Ellingsæter explains that: Sales of Pb-212 and Ra-224 can come in addition to the Th-228 agreements, without it coming at the expense of capacity for Th-228.
Good post I hadn't thought of that, AI answer here in the picture so one should probably take it with a grain of salt but if it's correct then the future is potentially very bright- ·2 päivää sittenPerspective (CATX) presented updated phase 1/2a data for VMT-α-NET targeting neuroendocrine tumors at ESMO today. VMT-α-NET is a Pb-212 treatment, and the study has 68 patients. * The response rate was 33 % in cohort 2 (5.0 mCi, 46 patients) and 50 % in cohort 3 (6.0 mCi, 20 patients). * Disease control was 89 % in cohort 2 and 95 % in cohort 3, and 72 % were progression-free at 18 months. * There was no dose-limiting toxicity and no grade 4–5 adverse events. * Phase 3 is scheduled to start in 2027, following a meeting with the FDA after phase 2 ("End-of-Phase-2"). Study centers are expected to be ready around New Year. https://lnkd.in/p/es2mbmdG
Have you all become doctors in here? I understand 5% of what you write 😅 and that 5% has taken time. It iaff seems like Thor's product is here to stay, in a couple of years we can maybe pop the champagne and laugh at this share price I hope 🫢🍿 Have a good weekend! 🙃 
·2 päivää sittenI am having a bit of fun following the largest owners in the companies where I have a few small bucks invested. And for Thor Medical, it is reasonably clear that the case is not viewed any worse than before by the largest owners. Among the top three, there are no changes; among the next dozen or so largest, there are also small changes, some have reduced slightly, others have added to their holdings. Interpret it as you will, I assume that if those closest to the company are sitting tight, the next news will not be of the wretched kind.... :)
On days like this people should just log off or buy more. Thinking TM pulls itself up afterwh. Man just has to have patience (I'm probably naive, but look at TM as a great investment for the future) Good weekend 🥰
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Nordnet Socialin käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tuotteita joiden kohde-etuutena tämä arvopaperi
Välittäjätilasto
Dataa ei löytynyt
2026 H1 - tulosraportti
58 päivää sitten
‧45 min
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Foorumi
Liity keskusteluun Nordnet Socialissa
- ·4 t sittenSharing this from Randy Peterson, the Q3/2026 update on manufacturing and supply chain in radiopharma. It hits the isotopes well because it shows how actively capacity is being built right now for the most important ones: Ac-225 (e.g. Actineer and BMS/RayzeBio), Lu-177 (ITM, Curium/MURR), Pb-212 (OranoMed), At-211 (Ionetix) and Cu-64 (C-Ray). At the same time, we see major investments in Canada (AtomVie, Isologic, Jubilant) and elsewhere to secure supply and scalable production. Fine overview, even though Thor Medical is unfortunately omitted. https://www.linkedin.com/pulse/q32026-radiopharmaceutical-newspart-ii-manufacturing-supply-peterson-myqbc?utm_source=share&utm_medium=member_ios&utm_campaign=share_via
- 1 päivä sittenChatGPT: What does this concretely mean for Thor Medical? The study provides positive signals for the further development of a new type of treatment against prostate cancer that has spread to other parts of the body. The results from the first study, TheraPb phase 1, support the researchers moving forward with the treatment ²¹²Pb-ADVC001. Now the treatment is being investigated further in phase 2, where the researchers are testing two doses – 160 and 200 MBq – and looking at how the dosing can be optimized, among other things in combination with other treatments. Here is the most important connection: AdvanCell, the company developing ADVC001, is already a customer of Thor Medical. Thor Medical supplies thorium-228 (Th-228), which AdvanCell uses as starting material to produce lead-212 (Pb-212) for the cancer treatment. In August 2025, AdvanCell increased its agreed purchase commitment from 100 to 150 million NOK over five years – an increase of 50 percent. It is also important that Thor Medical has several customers and programs than AdvanCell alone. The company reported a total order backlog of around 850 million NOK at the end of 2025, distributed across eight radiopharmaceutical companies. This provides several potential drivers for future demand.  My conclusion: This is relevant and potentially important news for Thor Medical. It supports the medical and commercial foundation for one of the company's customer's development programs. But for now, it is primarily a confirmation of the potential – not documentation that Thor Medical's revenues or profits will increase as a result of this exact study. For shareholders, it is crucial going forward whether phase 2 confirms the results, whether AdvanCell increases its actual orders, and whether Thor Medical manages to scale production and deliver with profitability.
- ·1 päivä sittenDid you know? Thor medical's order backlog of 850 million applies exclusively to Th228, which means that everything concerning Pb212 (and for that matter Ra-224) sales is extra revenue on top. When Scatec and several large investors pull out the shopping cart in a several times oversubscribed private placement, and make extra good room in the trunk to bring along as much as possible. Then one can perhaps think a little about how much revenue lies in the Pb212 initiative. I know at least that I wouldn't bet money on a private placement that makes revenues and margins worse, so here it is probably the opposite. Management has confirmed that these are separate revenue opportunities. Ellingsæter explains that: Sales of Pb-212 and Ra-224 can come in addition to the Th-228 agreements, without it coming at the expense of capacity for Th-228.Good post I hadn't thought of that, AI answer here in the picture so one should probably take it with a grain of salt but if it's correct then the future is potentially very bright
- ·2 päivää sittenPerspective (CATX) presented updated phase 1/2a data for VMT-α-NET targeting neuroendocrine tumors at ESMO today. VMT-α-NET is a Pb-212 treatment, and the study has 68 patients. * The response rate was 33 % in cohort 2 (5.0 mCi, 46 patients) and 50 % in cohort 3 (6.0 mCi, 20 patients). * Disease control was 89 % in cohort 2 and 95 % in cohort 3, and 72 % were progression-free at 18 months. * There was no dose-limiting toxicity and no grade 4–5 adverse events. * Phase 3 is scheduled to start in 2027, following a meeting with the FDA after phase 2 ("End-of-Phase-2"). Study centers are expected to be ready around New Year. https://lnkd.in/p/es2mbmdGHave you all become doctors in here? I understand 5% of what you write 😅 and that 5% has taken time. It iaff seems like Thor's product is here to stay, in a couple of years we can maybe pop the champagne and laugh at this share price I hope 🫢🍿 Have a good weekend! 🙃
- ·2 päivää sittenI am having a bit of fun following the largest owners in the companies where I have a few small bucks invested. And for Thor Medical, it is reasonably clear that the case is not viewed any worse than before by the largest owners. Among the top three, there are no changes; among the next dozen or so largest, there are also small changes, some have reduced slightly, others have added to their holdings. Interpret it as you will, I assume that if those closest to the company are sitting tight, the next news will not be of the wretched kind.... :)On days like this people should just log off or buy more. Thinking TM pulls itself up afterwh. Man just has to have patience (I'm probably naive, but look at TM as a great investment for the future) Good weekend 🥰
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Nordnet Socialin käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tarjoustasot
Määrä
Osto
-
Myynti
Määrä
-
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| 3 206 | - | - | ||
| 1 000 | - | - | ||
| 1 542 | - | - | ||
| 7 035 | - | - | ||
| 647 | - | - |
Huomioi, että vaikka osakkeisiin säästäminen on pitkällä aikavälillä tuottanut hyvin, tulevasta tuotosta ei ole takeita. On olemassa riski, että et saa sijoittamiasi varoja takaisin.
Rahastoja ja ETF:iä jotka omistavat osaketta
Mikään rahasto ei ilmoita osaketta kymmenen suurimman omistuksensa joukossa.
Asiakkaat katsoivat myös
Yhtiötapahtumat
Datan lähde: Quartr| Seuraava tapahtuma | |
|---|---|
2026 H2 - tulosraportti 26.2.2027 |
| Menneet tapahtumat | ||
|---|---|---|
2026 H1 - tulosraportti 28.8. | ||
2025 H2 - tulosraportti 26.2. | ||
2025 H1 - tulosraportti 29.8.2025 | ||
2024 H2 - tulosraportti 26.2.2025 | ||
2024 H1 - tulosraportti 30.8.2024 |
Tuotteita joiden kohde-etuutena tämä arvopaperi
Välittäjätilasto
Dataa ei löytynyt
2026 H1 - tulosraportti
58 päivää sitten
‧45 min
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Yhtiötapahtumat
Datan lähde: Quartr| Seuraava tapahtuma | |
|---|---|
2026 H2 - tulosraportti 26.2.2027 |
| Menneet tapahtumat | ||
|---|---|---|
2026 H1 - tulosraportti 28.8. | ||
2025 H2 - tulosraportti 26.2. | ||
2025 H1 - tulosraportti 29.8.2025 | ||
2024 H2 - tulosraportti 26.2.2025 | ||
2024 H1 - tulosraportti 30.8.2024 |
Tuotteita joiden kohde-etuutena tämä arvopaperi
Foorumi
Liity keskusteluun Nordnet Socialissa
- ·4 t sittenSharing this from Randy Peterson, the Q3/2026 update on manufacturing and supply chain in radiopharma. It hits the isotopes well because it shows how actively capacity is being built right now for the most important ones: Ac-225 (e.g. Actineer and BMS/RayzeBio), Lu-177 (ITM, Curium/MURR), Pb-212 (OranoMed), At-211 (Ionetix) and Cu-64 (C-Ray). At the same time, we see major investments in Canada (AtomVie, Isologic, Jubilant) and elsewhere to secure supply and scalable production. Fine overview, even though Thor Medical is unfortunately omitted. https://www.linkedin.com/pulse/q32026-radiopharmaceutical-newspart-ii-manufacturing-supply-peterson-myqbc?utm_source=share&utm_medium=member_ios&utm_campaign=share_via
- 1 päivä sittenChatGPT: What does this concretely mean for Thor Medical? The study provides positive signals for the further development of a new type of treatment against prostate cancer that has spread to other parts of the body. The results from the first study, TheraPb phase 1, support the researchers moving forward with the treatment ²¹²Pb-ADVC001. Now the treatment is being investigated further in phase 2, where the researchers are testing two doses – 160 and 200 MBq – and looking at how the dosing can be optimized, among other things in combination with other treatments. Here is the most important connection: AdvanCell, the company developing ADVC001, is already a customer of Thor Medical. Thor Medical supplies thorium-228 (Th-228), which AdvanCell uses as starting material to produce lead-212 (Pb-212) for the cancer treatment. In August 2025, AdvanCell increased its agreed purchase commitment from 100 to 150 million NOK over five years – an increase of 50 percent. It is also important that Thor Medical has several customers and programs than AdvanCell alone. The company reported a total order backlog of around 850 million NOK at the end of 2025, distributed across eight radiopharmaceutical companies. This provides several potential drivers for future demand.  My conclusion: This is relevant and potentially important news for Thor Medical. It supports the medical and commercial foundation for one of the company's customer's development programs. But for now, it is primarily a confirmation of the potential – not documentation that Thor Medical's revenues or profits will increase as a result of this exact study. For shareholders, it is crucial going forward whether phase 2 confirms the results, whether AdvanCell increases its actual orders, and whether Thor Medical manages to scale production and deliver with profitability.
- ·1 päivä sittenDid you know? Thor medical's order backlog of 850 million applies exclusively to Th228, which means that everything concerning Pb212 (and for that matter Ra-224) sales is extra revenue on top. When Scatec and several large investors pull out the shopping cart in a several times oversubscribed private placement, and make extra good room in the trunk to bring along as much as possible. Then one can perhaps think a little about how much revenue lies in the Pb212 initiative. I know at least that I wouldn't bet money on a private placement that makes revenues and margins worse, so here it is probably the opposite. Management has confirmed that these are separate revenue opportunities. Ellingsæter explains that: Sales of Pb-212 and Ra-224 can come in addition to the Th-228 agreements, without it coming at the expense of capacity for Th-228.Good post I hadn't thought of that, AI answer here in the picture so one should probably take it with a grain of salt but if it's correct then the future is potentially very bright
- ·2 päivää sittenPerspective (CATX) presented updated phase 1/2a data for VMT-α-NET targeting neuroendocrine tumors at ESMO today. VMT-α-NET is a Pb-212 treatment, and the study has 68 patients. * The response rate was 33 % in cohort 2 (5.0 mCi, 46 patients) and 50 % in cohort 3 (6.0 mCi, 20 patients). * Disease control was 89 % in cohort 2 and 95 % in cohort 3, and 72 % were progression-free at 18 months. * There was no dose-limiting toxicity and no grade 4–5 adverse events. * Phase 3 is scheduled to start in 2027, following a meeting with the FDA after phase 2 ("End-of-Phase-2"). Study centers are expected to be ready around New Year. https://lnkd.in/p/es2mbmdGHave you all become doctors in here? I understand 5% of what you write 😅 and that 5% has taken time. It iaff seems like Thor's product is here to stay, in a couple of years we can maybe pop the champagne and laugh at this share price I hope 🫢🍿 Have a good weekend! 🙃
- ·2 päivää sittenI am having a bit of fun following the largest owners in the companies where I have a few small bucks invested. And for Thor Medical, it is reasonably clear that the case is not viewed any worse than before by the largest owners. Among the top three, there are no changes; among the next dozen or so largest, there are also small changes, some have reduced slightly, others have added to their holdings. Interpret it as you will, I assume that if those closest to the company are sitting tight, the next news will not be of the wretched kind.... :)On days like this people should just log off or buy more. Thinking TM pulls itself up afterwh. Man just has to have patience (I'm probably naive, but look at TM as a great investment for the future) Good weekend 🥰
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Nordnet Socialin käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tarjoustasot
Määrä
Osto
-
Myynti
Määrä
-
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| 3 206 | - | - | ||
| 1 000 | - | - | ||
| 1 542 | - | - | ||
| 7 035 | - | - | ||
| 647 | - | - |
Huomioi, että vaikka osakkeisiin säästäminen on pitkällä aikavälillä tuottanut hyvin, tulevasta tuotosta ei ole takeita. On olemassa riski, että et saa sijoittamiasi varoja takaisin.
Rahastoja ja ETF:iä jotka omistavat osaketta
Mikään rahasto ei ilmoita osaketta kymmenen suurimman omistuksensa joukossa.
Asiakkaat katsoivat myös
Välittäjätilasto
Dataa ei löytynyt